As of September 30, 2026, Elanco Animal Health, Inc. carries a market capitalization of 9.98B, placing it among publicly traded companies globally. Its enterprise value stands at 12.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.98B |
| Enterprise Value | 12.84B |
Elanco Animal Health, Inc.'s next confirmed earnings release is scheduled for March 2, 2027.
| Earnings Date | 3/2/2027 |
As of September 30, 2026, Elanco Animal Health, Inc. has 499.73M shares outstanding.
| Shares Outstanding | 499.73M |
These figures are as of September 30, 2026. The price-to-sales ratio is 2.19, and the price-to-book ratio stands at 1.71.
| PS Ratio | 2.19 |
| PB Ratio | 1.71 |
| P/TBV Ratio | -9.42 |
| P/FCF Ratio | 27.96 |
| P/OCF Ratio | 18.38 |
As of September 30, 2026, Elanco Animal Health, Inc. trades at an EV/EBITDA multiple of 17.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 90.99 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.84B versus a market cap of 9.98B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 2.83 |
| EV / EBITDA | 17.05 |
| EV / EBIT | 90.99 |
As of September 30, 2026, Elanco Animal Health, Inc. maintains a current ratio of 2.09, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.93, indicating elevated leverage, while an interest coverage ratio of 3.35 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.09 |
| Quick Ratio | 0.86 |
| Debt / Equity | 55.93 |
| Debt / EBITDA | 4.34 |
| Interest Coverage | 3.35 |
Over the twelve months ended September 30, 2026, Elanco Animal Health, Inc. posted a negative return on equity (ROE) of -2.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.09, reflecting losses generated across the asset base. The company generates approximately 458,796.00 in revenue per employee across its workforce of 9,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times Elanco Animal Health, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -2.20 |
| Return on Assets (ROA) | -1.09 |
| Revenue Per Employee | 458,796.00 |
| Employee Count | 9,900.00 |
| Inventory Turnover | 1.28 |
Over the twelve months ended September 30, 2026, Elanco Animal Health, Inc. recorded 48.53M in income tax expense. The company reported a pretax loss of -81.17M and -129.70M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 48.53M |
As of the close on November 17, 2026, Elanco Animal Health, Inc.'s stock has gained approximately 30.85% over the past 52 weeks. The 50-day moving average sits at 20.84, while the 200-day moving average is 20.73.
| 52-Week Price Change | 30.85% |
| 50-Day Moving Average | 20.84 |
| 200-Day Moving Average | 20.73 |
Over the twelve months ended September 30, 2026, Elanco Animal Health, Inc. generated 4.54B in revenue and converted that into -129.70M in net income, yielding earnings per share of -0.26. EBITDA reached 753.48M, while operating income came in at 344.10M.
| Revenue | 4.54B |
| Gross Profit | 2.55B |
| Operating Income | 344.10M |
| Pretax Income | -81.17M |
| Net Income | -129.70M |
| EBITDA | 753.48M |
| EBIT | 141.17M |
| Earnings Per Share (EPS) | -0.26 |
As of September 30, 2026, Elanco Animal Health, Inc. holds 410.27M in cash and equivalents against 3.27B in total debt, resulting in a net debt position of 2.86B. Total book value stands at 5.85B, with working capital of 1.71B providing operational flexibility.
| Cash & Cash Equivalents | 410.27M |
| Total Debt | 3.27B |
| Net Debt | 2.86B |
| Equity (Book Value) | 5.85B |
| Book Value Per Share | 11.70 |
| Working Capital | 1.71B |
Elanco Animal Health, Inc. produced 541.73M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -181.75M in capital expenditures, free cash flow totaled 359.98M - equivalent to 0.72 per share.
| Operating Cash Flow | 541.73M |
| Capital Expenditures | -181.75M |
| Free Cash Flow | 359.98M |
| FCF Per Share | 0.72 |
Over the twelve months ended September 30, 2026, Elanco Animal Health, Inc. posted a gross margin of 56.18, reflecting its pricing power and cost economics. The operating margin of 7.58 and net profit margin of -2.86 provide insight into operational efficiency.
| Gross Margin | 56.18 |
| Operating Margin | 7.58 |
| Pretax Margin | -1.79 |
| Profit Margin | -2.86 |
| EBITDA Margin | 16.59 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 3.58, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Elanco Animal Health, Inc. shareholders.
| Shareholder Yield | 3.30 |
| FCF Yield | 3.58 |
As of September 30, 2026, Elanco Animal Health, Inc. has an Altman Z-Score of 2.08, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.08 |